Endpoints News 生物医药· Max Gelman·· 2026-10-08AI 评分44
Zealand与Roche发布amylin药物肥胖和糖尿病II期研究初步结果,Lilly仍是障碍
Zealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacle
AI 导读
Zealand Pharma与Roche公布其amylin药物在肥胖和糖尿病治疗中的II期中期数据,旨在与Eli Lilly竞争。尽管数据显示潜力,但Lilly在此领域占据主导地位,构成主要竞争障碍。该研究结果目前处于初步阶段,尚未最终确证。
正文
Zealand Pharma and Roche rolled out some mid-stage data for their amylin drug in obesity and diabetes, hoping to compete with Eli Lilly.
In a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news